Data / Form D filings / PROVECTUS BIOPHARMACEUTICALS, INC.
PROVECTUS BIOPHARMACEUTICALS, INC.: Form D filings
PROVECTUS BIOPHARMACEUTICALS, INC., a pharmaceuticals company in Knoxville, TN, filed 17 Form D notices with the SEC between 2009 and 2024. The latest, on July 17, 2024, reports an offering of $10 million with nothing sold yet.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 800 S. GAY STREET, SUITE 1610, Knoxville, TN, 37929
- Phone
- (866) 594-5999
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- $1 - $1,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 315545
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 17, 2024 | New notice | $10,000,000 | $0 | $10,000,000 | 0 | Yet to occur | sec.gov |
| Oct 28, 2022 | New notice | $5,000,000 | $317,500 | $4,682,500 | 2 | Sep 23, 2022 | sec.gov |
| Aug 30, 2021 | New notice | $5,000,000 | $200,000 | $4,800,000 | 1 | Aug 16, 2021 | sec.gov |
| Oct 15, 2014 | New notice | $15,000,000 | $0 | $15,000,000 | 0 | Yet to occur | sec.gov |
| Apr 17, 2014 | New notice | $5,000,000 | $3,373,250 | $1,626,750 | 17 | Apr 2, 2014 | sec.gov |
| Sep 26, 2013 | New notice | $16,000,000 | $7,798,037 | $8,201,963 | 67 | Mar 12, 2013 | sec.gov |
| Mar 8, 2013 | New notice | $2,550,000 | $2,550,000 | 3 | Feb 22, 2013 | sec.gov | |
| Nov 19, 2012 | New notice | $5,000,000 | $2,034,675 | $2,965,325 | 5 | Nov 2, 2012 | sec.gov |
| Aug 3, 2012 | New notice | $4,999,999 | $2,077,796 | $2,922,203 | 16 | Mar 28, 2012 | sec.gov |
| Mar 22, 2012 | New notice | $2,499,999 | $499,999 | $2,000,000 | 6 | Sep 29, 2011 | sec.gov |
| May 5, 2011 | New notice | $5,000,000 | $4,615,300 | $384,700 | 26 | Apr 20, 2011 | sec.gov |
| May 13, 2010 | New notice | $1,000,000 | $200,000 | $800,000 | 0 | Apr 29, 2010 | sec.gov |
| Apr 6, 2010 | New notice | $1,271,900 | $1,271,900 | 14 | Mar 19, 2010 | sec.gov | |
| Mar 26, 2010 | Amendment | $10,363,327 | $7,613,327 | $2,750,000 | 90 | Apr 7, 2009 | sec.gov |
| Mar 24, 2010 | New notice | $10,000,000 | $7,937,499 | $2,062,501 | 36 | Mar 11, 2010 | sec.gov |
| Aug 7, 2009 | Amendment | $4,507,176 | $4,507,176 | 90 | Apr 7, 2009 | sec.gov | |
| Jun 30, 2009 | New notice | $3,500,000 | $2,712,000 | $788,000 | 47 | May 26, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Edward Pershing | Director | |
| Dominic Rodrigues | Director | |
| John Lacey, III | Director | |
| Eric Wachter | Executive Officer | |
| Heather Raines | Executive Officer | |
| Webster Bailey | Director |
Every Form D from the week of Jul 15, 2024 · All recent filings in Tennessee · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what PROVECTUS BIOPHARMACEUTICALS, INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.